Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788087 | 1.00 | CES2 (0.37) | CES2CA1RECQLSMPD1GLA | |
| SCHEMBL6848142 | 1.00 | CES2 (0.37) | CES2CA1RECQLSMPD1GLA | |
| SCHEMBL10430528 | 1.00 | CES2 (0.37) | CES2CA1RECQLSMPD1GLA | |
| SCHEMBL486057 | 1.00 | CES2 (0.37) | CES2CA1RECQLSMPD1GLA | |
| SCHEMBL2350328 | 1.00 | CES2 (0.37) | CES2CA1RECQLSMPD1GLA | |
| Lithium Ion SCHEMBL6258171 | 0.97 | CES2 (0.37) | CES2SMPD1MEN1MAPTKMT2A | |
| Lithium Ion SCHEMBL6258184 | 0.97 | CES2 (0.37) | CES2SMPD1MEN1MAPTKMT2A | |
| SCHEMBL6261811 | 0.89 | FFAR3 (0.32) | CA1 | |
| SCHEMBL289231 | 0.84 | TDP1 (0.39) | TSHRGPR84MEN1KMT2A | |
| SCHEMBL12474251 | 0.84 | TDP1 (0.39) | TSHRGPR84MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2337544-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | Living Proof, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20090068255-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | LIVING PROOF, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2008134712-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | LIVING PROOF, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008070368-A2 | METHODS AND COMPOSITIONS FOR SKIN CARE | LIVING PROOF, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-6395264-B1 | CONTAINING A WATER SOLUBLE OR DISPERSABLE FIXATIVE POLYMER; NEUTRALIZING AGENT; HYDROCARBON BASED SURFACTANT SUCH AS SODIUM DIOCTYL SUCCINATE; AN ORGANIC OR INORGANIC SALT; ALCOHOL AND WATER | UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO, INC. | 2002-05-28 | — | — | US | disclosed |
| US-20020028187-A1 | LOW VOC HAIR SPRAY COMPOSITIONS HAVING ENHANCED STYLING BENEFITS | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001070179-A1 | LOW VOC HAIR SPRAY COMPOSITIONS HAVING ENHANCED STYLING BENEFITS | UNILEVER PLC (GB) | 2001-09-27 | — | — | WO | disclosed |
| WO-2000057846-A1 | LOW VOC HAIR SPRAY COMPOSITIONS HAVING ENHANCED STYLING BENEFITS | UNILEVER PLC (GB) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068255-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | MMP1, MMP9, MMP17 | CA1 4573/4885CES2 2512/4885RECQL 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.